ALIROCUMAB

Information current as at: 1 June 2026

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.


Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Praluent®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:
Sanofi-Aventis Australia Pty Ltd
Condition/indication:
(therapeutic use)
  • Familial heterozygous hypercholesterolaemia and non-familial hypercholesterolaemia.
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC Submission type:
New listing (Category 4)
Comment:
--
Other PBAC consideration:

Progress Details

Submission received for:
March 2023 PBAC meeting
Opportunity for consumer comment:
Open 23/11/2022 and close 25/01/2023 (see PBS Website)
PBAC meeting:
Held on 08/03/2023
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Public Summary Document:
PBAC Public Summary Documents – March 2023
Case ID
a629
Page last updated
31 March 2026
Return to the Medicine Status Listing
v.9.19